Beverly S. Mitchell, M.D.

Publication Details

• Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response.

  Gandhi V, Plunkett W, Rodriguez CO, Nowak BJ, Du M, Ayres M, Kisor DF, Mitchell BS, Kurtzberg J, Keating MJ. J Clin Oncol. 1998; 16 (11): 3607-15

  In vitro investigations with arabinosylguanine (ara-G) demonstrated potent cytotoxicity to T-lymphoblastoid cell lines. The goals of the present study were to evaluate GW506U78, a prodrug of ara-G, against human hematologic malignancies and to determine its pharmacokinetics in plasma and cells.

  PubMedID: 9817282